Trial Profile
An Open-label Dose Escalation Study to Estimate MTD, Identify DLTs and Study Pharmacokinetics Following a Single Dose of Intracranially Administered Temozolomide-based SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed Glioblastoma
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms TARGLIO
- Sponsors Double Bond Pharmaceutical
- 04 Jul 2023 Planned End Date changed from 1 Aug 2025 to 1 Dec 2025.
- 04 Jul 2023 Planned primary completion date changed from 1 Jun 2025 to 1 Jul 2025.
- 04 Jul 2023 Planned initiation date changed from 1 Jul 2023 to 1 Jul 2024.